Crack cocaine is a freebase form of the stimulant drug cocaine that can be smoked. It is produced by processing powdered cocaine hydrochloride with a base, typically sodium bicarbonate (baking soda) or ammonia, and water, resulting in a solid, crystalline substance that "cracks" into fragments when cooled. These fragments are commonly referred to as "crack rocks."
Chemical composition and preparation
- Active ingredient: The psychoactive component is cocaine base, chemically known as benzoylmethylecgonine.
- Manufacturing process: Powdered cocaine hydrochloride is dissolved in water and mixed with a base (e.g., sodium bicarbonate). The mixture is heated, causing the cocaine base to precipitate as solid crystals. Upon cooling, the solid breaks into irregular pieces that emit a characteristic cracking sound when heated, giving the drug its name.
Pharmacology
- Route of administration: Primarily smoked; inhalation delivers the drug rapidly to the pulmonary alveoli, allowing swift absorption into the bloodstream.
- Onset and duration: Effects begin within seconds to a minute, peak within a few minutes, and typically last 5–10 minutes, shorter than the 30–60 minute duration of intranasal or intravenous cocaine.
- Mechanism of action: Cocaine blocks the reuptake of monoamine neurotransmitters—dopamine, norepinephrine, and serotonin—by inhibiting their transporters, leading to increased synaptic concentrations and stimulant effects.
Historical context
- Emergence: Crack cocaine appeared in the United States in the early 1980s, coinciding with the introduction of inexpensive, rapid‑acting forms of cocaine. Its low production cost and high potency contributed to widespread illicit use, especially in urban areas.
- Public health response: The surge in crack use prompted a series of policy and law‑enforcement actions, including the United States’ Anti‑Drug Abuse Act of 1986, which established significantly higher mandatory minimum sentences for crack compared with powdered cocaine.
Legal status
- International control: Cocaine and its derivatives, including crack, are listed under Schedule I of the United Nations Single Convention on Narcotic Drugs (1961), indicating a high potential for abuse and no recognized medical use.
- United States: Classified as a Schedule II substance under the Controlled Substances Act, acknowledging limited medical use (e.g., topical anesthetic) but a high risk of dependence. Possession, manufacture, and distribution are illegal except under tightly regulated circumstances.
- Other jurisdictions: Most countries similarly categorize crack cocaine as an illegal controlled substance with severe penalties for illicit handling.
Health effects
- Acute effects: Euphoria, increased energy, heightened alertness, tachycardia, hypertension, vasoconstriction, hyperthermia, dilated pupils, and loss of appetite. Psychological effects may include paranoia, anxiety, and agitation.
- Adverse events: Risk of cardiovascular complications (myocardial infarction, arrhythmia), cerebrovascular accidents (stroke), respiratory problems (pulmonary edema, acute lung injury), and seizures.
- Addiction and dependence: Rapid onset and brief duration promote repeated dosing, leading to a high potential for psychological dependence. Withdrawal symptoms include dysphoria, fatigue, increased appetite, and vivid dreams.
- Long‑term consequences: Chronic use is associated with cognitive deficits, mood disorders, dental deterioration ("crack mouth"), and increased risk of infectious disease transmission due to associated high‑risk behaviors.
Societal impact
- Epidemiology: Use peaked in the United States during the late 1980s and early 1990s, with a subsequent decline in prevalence but persistent regional pockets of high consumption.
- Economic burden: Costs arise from healthcare utilization, law‑enforcement expenditures, lost productivity, and social services.
- Harm‑reduction approaches: Programs such as needle exchange, supervised consumption sites, and medication‑assisted treatment (e.g., contingency management, cognitive‑behavioral therapy) have been employed to mitigate health risks.
Research and treatment
- Pharmacotherapy: No FDA‑approved medication specifically for cocaine or crack dependence. Clinical trials have examined agents such as modafinil, topiramate, and disulfiram, with mixed results.
- Behavioral interventions: Cognitive‑behavioral therapy, contingency management, and motivational interviewing are the primary evidence‑based psychosocial treatments for crack cocaine use disorder.
References
(Encyclopedic entries typically cite peer‑reviewed literature, governmental reports, and reputable drug information databases; specific citations are omitted here for brevity.)